Skip to main content

Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women.

Publication ,  Journal Article
Gadde, KM; Parker, CB; Maner, LG; Wagner, HR; Logue, EJ; Drezner, MK; Krishnan, KR
Published in: Obes Res
September 2001

OBJECTIVE: On the basis of the clinical observations that bupropion facilitated weight loss, we investigated the efficacy and tolerability of this drug in overweight and obese adult women. RESEARCH METHODS AND PROCEDURES: A total of 50 overweight and obese (body mass index: 28.0 to 52.6 kg/m(2)) women were included. The core component of the study was a randomized, double-blind, placebo-controlled comparison for 8 weeks. Bupropion or placebo was started at 100 mg/d with gradual dose increase to a maximum of 200 mg twice daily. All subjects were prescribed a 1600 kcal/d balanced diet and compliance was monitored with food diaries. Responders continued the same treatment in a double-blind manner for an additional 16 weeks to a total of 24 weeks. There was additional single-blind follow-up treatment for a total of 2 years. RESULTS: Subjects receiving bupropion achieved greater mean weight loss (last-observation-carried-forward analysis) over the first 8 weeks of the study (p = 0.0001): 4.9% +/- 3.4% (n = 25) for bupropion treatment compared with 1.3% +/- 2.4% (n = 25) for placebo treatment. For those who completed the 8 weeks, the comparison was 6.2% +/- 3.1% (n = 18) vs. 1.6% +/- 2.9% (n = 13), respectively(p = 0.0002), with 12 of 18 of the bupropion subjects (67%) losing over 5% of baseline body weight compared with 2 of 13 in the placebo group (15%; p = 0.0094). In the continuation phase, 14 bupropion responders who completed 24 weeks achieved weight loss of 12.9% +/- 5.6% with fat accounting for 73.5% +/- 3.7% of the weight lost and no change in bone mineral density as assessed by DXA. Bupropion was generally well-tolerated in this sample. DISCUSSION: Bupropion was more effective than placebo in achieving weight loss at 8 weeks in overweight and obese adult women in this preliminary study. Initial responders to bupropion benefited further in the continuation phase.

Duke Scholars

Published In

Obes Res

DOI

ISSN

1071-7323

Publication Date

September 2001

Volume

9

Issue

9

Start / End Page

544 / 551

Location

United States

Related Subject Headings

  • Weight Loss
  • Treatment Outcome
  • Obesity
  • Middle Aged
  • Humans
  • Follow-Up Studies
  • Female
  • Energy Intake
  • Endocrinology & Metabolism
  • Drug Administration Schedule
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gadde, K. M., Parker, C. B., Maner, L. G., Wagner, H. R., Logue, E. J., Drezner, M. K., & Krishnan, K. R. (2001). Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res, 9(9), 544–551. https://doi.org/10.1038/oby.2001.71
Gadde, K. M., C. B. Parker, L. G. Maner, H. R. Wagner, E. J. Logue, M. K. Drezner, and K. R. Krishnan. “Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women.Obes Res 9, no. 9 (September 2001): 544–51. https://doi.org/10.1038/oby.2001.71.
Gadde KM, Parker CB, Maner LG, Wagner HR, Logue EJ, Drezner MK, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res. 2001 Sep;9(9):544–51.
Gadde, K. M., et al. “Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women.Obes Res, vol. 9, no. 9, Sept. 2001, pp. 544–51. Pubmed, doi:10.1038/oby.2001.71.
Gadde KM, Parker CB, Maner LG, Wagner HR, Logue EJ, Drezner MK, Krishnan KR. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res. 2001 Sep;9(9):544–551.

Published In

Obes Res

DOI

ISSN

1071-7323

Publication Date

September 2001

Volume

9

Issue

9

Start / End Page

544 / 551

Location

United States

Related Subject Headings

  • Weight Loss
  • Treatment Outcome
  • Obesity
  • Middle Aged
  • Humans
  • Follow-Up Studies
  • Female
  • Energy Intake
  • Endocrinology & Metabolism
  • Drug Administration Schedule